Quick Links

MNI news

How HIV affects the brain

Study tracks patients to better understand effects and possible treatments December 1 is World AIDS Day, a time to raise awareness about a disease that has afflicted 70 million people worldwide, 35 million of whom have died as a result.

Published on : 01 Dec 2016

Epileptic encephalopathy linked to protein trafficking gene

Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.

Published on : 28 Nov 2016

MNI researchers receive funding to study ARSACS

Two researchers at the Montreal Neurological Institute and Hospital (MNI) of McGill University have received funding to study a devastating neurodegenerative disease that first appears in toddlers just as they are beginning to walk.

Published on : 24 Nov 2016

Major ALS Research Funding Announced

MNI scientists will study stem cells, genetic mutations to develop new treatments Researchers at the Montreal Neurological Institute of McGill University who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23 by the ALS Society of Canada in partnership with Brain Canada.

Published on : 23 Nov 2016

Olfactory perception influenced by background and semantic information

When two people smell the same thing, they can have remarkably different reactions, depending on their cultural background. Researchers at the Neuro have found that even when two cultures share the same language and many traditions, their reactions to the same smells can be different.

Published on : 21 Nov 2016

The Neuro Celebrates #GivingTuesday on November 29

#GivingTuesday is a global day of giving, created to counteract the consumerism-based Black Friday and Cyber Monday. This year, The Neuro is celebrating #GivingTuesday by inviting the community to fund the Giving Tuesday Travel Award – which will allow a talented student or fellow to present their research at a national or international scientific meeting.

Category :
Published on : 08 Nov 2016

Evans receives Quebec honour

2016 Prix Wilder-Penfield recognizes monumental work in brain imaging and mapping Dr. Alan Evans has become the latest researcher to receive the Province of Quebec’s most prestigious scientific award, the 2016 Prix Wilder-Penfield, named after The Neuro’s founder. 

Category :
Published on : 05 Nov 2016

Quebec federation honours Dr. Tampieri

Neuroradiologist recognized for her innovations in healthcare The Quebec Federation of Medical Specialists (Fédération des médecins spécialistes du Québec), an umbrella organization embracing medical specialist groups in the province, has chosen Dr. Donatella Tampieri of the Montreal Neurological Institute and Hospital (The Neuro) as one of three recipients of its 2016 Prix d’excellence en innovations des soins de santé. The award recognizes Dr. Tampieri’s exceptional career in providing quality healthcare that is accessible, efficient, and safe.

Category :
Published on : 04 Nov 2016

Researchers identify gene associated with intracranial aneurysm in French-Canadian population

Scientists have identified a gene in the French-Canadian population that predisposes them to the development of intracranial aneurysm (IA), a potentially life threatening neurological condition that is responsible for approximately 500,000 deaths worldwide per year, half of which occur in people less than 50 years of age. Using genetic analysis, the team of researchers found rare variations of one gene, RNF213, that appeared more frequently in IA patients than in the control group. Both patients and the control group came from French-Canadian families.

Published on : 31 Oct 2016

A Brilliant Success

A Brilliant Night raises $1 million for brain cancer research A Brilliant Night, raised an astounding $1 million for brain cancer research at its gala event on Oct. 19.

Category :
Published on : 27 Oct 2016

Essential tremor sufferers needed for groundbreaking study

You probably know someone who has it. It is the most common movement disorder, yet most people don’t even know its name. Essential tremor affects nearly one per cent of the world’s population, increasing to four per cent of those over 40. The involuntary shaking of hands is the most common symptom, but symptoms can also include shaking of the head and legs.

Published on : 21 Oct 2016

The Neuro names Susan Cameron Cook Neuro-Palliative Care Program

The Montreal Neurological Institute and Hospital (The Neuro) is pleased to announce a new initiative designed to ease the suffering of seriously ill patients through specialized consultation and comprehensive care. The Susan Cameron Cook Neuro-Palliative Care Program, named in honour of Susan Cameron Cook, whose family provided vital seed funding for this initiative, has the goal of reducing the mental and physical suffering of neurological patients and their families in the journey from diagnosis of a terminal illness to end of life.

Published on : 17 Oct 2016

Dr. Guy Rouleau receives national award for significant contributions to world of science

Dr. Guy Rouleau, Director of the Montreal Neurological Institute and Hospital at McGill University and the McGill University Health Centre, has been chosen to receive another major award recognizing his outstanding scientific career. The national organization representing Canadian francophone doctors, Médecins francophones du Canada, is bestowing on him its 2016 Prix de l’oeuvre scientifique.

Published on : 13 Oct 2016

A Brilliant Night 2016

Inspiring event to raise money for brain cancer research An evening filled with personal stories from those whose lives have been affected by brain cancer will once again contribute to the fight against the disease.

Published on : 04 Oct 2016

KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC

KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015. The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.

Published on : 03 Oct 2016